Regeneron to invest $100 million in bluebird, jointly develop cancer therapies

Regeneron to invest $100 million in bluebird, jointly develop cancer therapies


Regeneron Pharmaceuticals Inc said on Monday it will invest $100 million in cancer drug developer bluebird bio Inc, and the companies will jointly develop new cell therapies for cancer. The investment will be at $238.10 per share, a premium of nearly 59 percent over bluebird's Friday closing price.



from Biotech News